Upadacitinib Monotherapy for Treatment of Pyoderma Gangrenosum: A Case Series

This case series highlights the successful use of upadacitinib monotherapy, a selective JAK1 inhibitor, in treating pyoderma gangrenosum (PG), a rare inflammatory skin disorder. The study reports complete reepithelialization of lesions and resolution of pain in patients, suggesting upadacitinib's potential as a safe and effective treatment for resistant and recurring PG lesions. These findings support the promise of JAK1 inhibitors as targeted therapies for PG and suggest the need for further investigation in larger clinical trials.